Lundbeck expects to return to profitability in 2016

10 February 2016

Denmark-based CNS specialist Lundbeck (LUND: CO) saw its shares rise 17.25% to 242.60 Danish kroner this morning, after it reported better that expected financials, posting fourth-quarter 2015 revenue of 3.73 billion kroner ($556.7 million) and a loss of 432 million kroner, compared with consensus expectations of sales at 3.46 million kroner and a loss of 314 million kroner.

For the full year, revenues came in at 14.59 billion kroner, up 8% but flat in local currencies. Core earnings before interest and taxes (EBIT) was down 31% at 847 million kroner, with reported EBIT seeing a loss of 6.82 billion kroner compared with a profit of 99 million kroner in 2014.

For 2016, Lundbeck expects revenue of around 13.8-14.2 billion kroner and EBIT is expected to reach 1.0-1.2 billion kroner.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK